At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Mar 5, 2026 at 07:00 ET
MediWound reported a decline in Q4 and full-year 2025 revenue, driven by lower development services due to the U.S. government shutdown and reduced product sales to Vericel. Despite higher R&D spending on the EscharEx Phase III trial, the company maintained a strong cash position of $53.6 million and reaffirmed its 2026–2028 revenue guidance. The stock remains speculative, tied to upcoming clinical and regulatory catalysts.
- Q4 2025 revenue was $1.9 million, down 67% from $5.8 million in Q4 2024
- Full-year 2025 revenue was $17.0 million, down from $20.2 million in 2024
- Net loss for 2025 was $23.9 million, or $2.10 per share, compared to $30.2 million, or $3.03 per share, in 2024
- Cash balance increased to $53.6 million at year-end, up from $43.6 million, due to a $30 million registered direct offering
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access